Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AbbVie
ABBV · NYSE · Pharmaceuticals
$286.01−6.81 (−2.33%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
0 open-market purchases and 2 open-market sales by insiders of ABBV between Jun 6, 2026 and today, placed against the company's last 4 earnings releases. The latest on file was filed Oct 30, 2026. The data provider lists the next release for Feb 2, 2027; that date may change.
PurchaseSale30 days before a release30 days after
Trades in the 30 days around each of the last earnings releases
Jeffrey Ryan Stewart, EVP, CHIEF COMMERCIAL OFFICER, Nov 9, 2026, about $11.9M. Sold 10 days after the company's previous earnings release on 2026-10-30Form 4
Nicholas Donoghoe, EVP, CHIEF BUS/STRAT OFFICER, Aug 14, 2026, about $8.18M. Sold 14 days after the company's previous earnings release on 2026-07-31Form 4
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies